M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

Early Phase 1

Recruiting

Conditions: Smoking
Lung Cancer

Interventions: Other: Best Practice
Drug: Nicotine Patch
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Tobacco Cessation Counseling

First Posted Date: 2019-12-16

Last Posted Date: 2024-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 520

Registration Number: NCT04200534

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Texas Health Science Center at Tyler, Tyler, Texas, United States

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Early Phase 1

Not yet recruiting

Conditions: Metastatic Sarcoma
Recurrent Sarcoma
Resectable Sarcoma

Interventions: Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Device: Drug Delivery Microdevice
Drug: Everolimus
Biological: Ganitumab
Drug: Ifosfamide
Drug: Irinotecan
Drug: Pazopanib
Drug: Polyethylene Glycol
Drug: Temozolomide
Drug: Temsirolimus
Procedure: Therapeutic Conventional Surgery
Drug: Vincristine

First Posted Date: 2019-12-13

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04199026

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

Not Applicable

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Communication Intervention
Other: Questionnaire Administration
Other: Waiting List

First Posted Date: 2019-12-12

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT04196972

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

Recruiting

Conditions: Partner
Stage IIIB Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Spouse
Stage II Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Cancer Survivor
Stage I Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8

Interventions: Device: Accelerometer
Other: Ecological Momentary Assessment
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2019-12-06

Last Posted Date: 2024-08-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT04189770

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2019-12-06

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04189757

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

Phase 2

Active, not recruiting

Conditions: Retroperitoneal Sarcoma

Interventions: Drug: Liposomal Bupivacaine
Drug: Quadratus Lumborum Block
Other: Questionnaire Administration

First Posted Date: 2019-12-06

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 113

Registration Number: NCT04189783

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

Phase 3

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Drug: Fentanyl Citrate Buccal Tablet
Other: Physical Performance Testing
Drug: Morphine
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-12-05

Last Posted Date: 2024-06-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT04188418

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Phase 2

Active, not recruiting

Conditions: Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Myeloid Leukemia
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Acute Myeloid Leukemia

Interventions: Drug: Decitabine
Drug: Ponatinib
Drug: Venetoclax

First Posted Date: 2019-12-05

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04188405

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy

Not Applicable

Recruiting

Conditions: Radiation Therapy Patient
Glioma

Interventions: Device: Pedometer
Device: FitBit
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-12-05

Last Posted Date: 2024-08-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT04186832

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

Completed

Conditions: Recurrent Malignant Neoplasm
Metastatic Malignant Neoplasm
Advanced Malignant Neoplasm
Locally Advanced Malignant Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-12-05

Last Posted Date: 2022-03-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 351

Registration Number: NCT04186884

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy